Resource Logo

HIV infection in women: a eight year longitudinal observational study.


Int Conf AIDS. 1994 Aug 7-12;10(1):313 (abstract no. PC0184). Unique

OBJECTIVE: To study the epidemiology, clinical characteristics and evolution in a cohort of HIV-infected women in the South of Spain. METHODS: A observational study of 242 HIV+ women from their first study to the last clinical control or death, between 1/86-12/93. Kaplan Meier and logrank tests were used for survival analysis. RESULTS: Median age was 30 years. HIV risks included IDU in 64%, heterosexual contact in 32%, transfusion in 3% and unknown in 1%. The proportion of heterosexually infected patients showed an increase from 16% in 1986-1987 to 50% in 1992-1993. Only 143 patients (59%) are periodically controlled. At entry 31 (29%) had more than 500 CD4/mm, 45 (42%O had between 200-500 CD4/mm, 17 (16%) between 50-200 CD4/mm and 13 (12%) less than 50 CD4/mm. Of the 33 (23%) women with AIDS, the inicial AIDS defining conditions were Candida esophagitis (8), PCP (8), caquexia (6), disseminated tuberculosis (5), cerebral toxoplasmosis (3) and CMV iotinitis, Kaposi sarcoma and lymphoma (1u each). 16 (11%) women have died. The median survival time was 5.5 years from the first clinical control and 20 months from AIDS diagnosis. CD4 count at entry was the most powerful marker of survival. No other survival differences were detected based on risk factor or AIDS-defining diagnosis. Overall survival was similar to that of men. CONCLUSIONS: 1) In this area, IDU is the first HIV-risk behavior in women and heterosexual transmission is increasing very quickly. 2) Only 59% of HIV-infected women have periodic follow up. 3) CD4 count at entry is the stronger marker of evolution.

Acquired Immunodeficiency Syndrome/DIAGNOSIS/MORTALITY Adult AIDS-Related Opportunistic Infections/EPIDEMIOLOGY Cohort Studies Female Human *HIV Infections/DIAGNOSIS/EPIDEMIOLOGY HIV Seropositivity Risk Factors Sex Behavior Spain/EPIDEMIOLOGY Survival Rate ABSTRACT


Information in this article was accurate in December 30, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.